128 related articles for article (PubMed ID: 34254266)
41. Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience.
Schelker RC; Herr W; Reichle A; Vogelhuber M
BMC Cancer; 2018 Oct; 18(1):1000. PubMed ID: 30340554
[TBL] [Abstract][Full Text] [Related]
42. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
43. Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment - A systematic review.
Tavares A; Moreira I
Crit Rev Oncol Hematol; 2021 Apr; 160():103294. PubMed ID: 33675907
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
45. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
46. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract][Full Text] [Related]
47. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Go SI; Kim HG; Kang MH; Park S; Lee GW
BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
[TBL] [Abstract][Full Text] [Related]
48. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
49. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
50. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
51. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
[TBL] [Abstract][Full Text] [Related]
52. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
53. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
54. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.
Chaiwatanatorn K; Stamaratis G; Opeskin K; Firkin F; Nandurkar H
Leuk Lymphoma; 2009 Oct; 50(10):1666-75. PubMed ID: 19757311
[TBL] [Abstract][Full Text] [Related]
55. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
[TBL] [Abstract][Full Text] [Related]
56. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
[TBL] [Abstract][Full Text] [Related]
57. Retrospective Analysis of Treatment Outcomes and Geriatric Assessment in Elderly Malignant Lymphoma Patients.
Naito Y; Sasaki H; Takamatsu Y; Kiyomi F; Tamura K
J Clin Exp Hematop; 2016; 56(1):43-9. PubMed ID: 27334857
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
Hong J; Park S; Park J; Kim HS; Kim KH; Ahn JY; Rim MY; Jung M; Sym SJ; Cho EK; Shin DB; Lee JH
Leuk Lymphoma; 2011 Oct; 52(10):1904-12. PubMed ID: 21718130
[TBL] [Abstract][Full Text] [Related]
59. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.
Ngo L; Hee SW; Lim LC; Tao M; Quek R; Yap SP; Loong EL; Sng I; Hwan-Cheong TL; Ang MK; Ngeow J; Tham CK; Tan MH; Lim ST
Leuk Lymphoma; 2008 Mar; 49(3):462-9. PubMed ID: 18297522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
